



Our STN: BL 125591/383

SUPPLEMENT APPROVAL

June 09, 2023

CSL Behring Lengnau AG
Attention: Edward T. Gallagher
CSL Behring LLC
1020 First Avenue
P.O. Box 61501
King of Prussia, PA 19406-0901

Dear Mr. Gallagher:

We have approved your request received December 8, 2022, to supplement your Biologics License Application (BLA), submitted under section 351(a) of the Public Health Service Act, for Antihemophilic Factor (Recombinant), Single Chain [AFSTYLA[®]] and to include information from study CSL627_3001 on previously untreated patients in Sections 6 ADVERSE REACTIONS (6.1 Clinical Trials Experience, 6.2 Immunogenicity), 8.4 Pediatric Use, and 14 CLINICAL STUDIES of the prescribing information for AFSTYLA[®].

LABELING

Under 21 CFR 201.57(c)(18), patient labeling must be referenced in section 17 PATIENT COUNSELING INFORMATION. Patient labeling must be available and may either be reprinted immediately following the full prescribing information of the package insert or accompany the prescription product labeling.

We hereby approve the draft content of labeling Package Insert submitted under amendment 6, dated June 6, 2023.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, please submit the final content of labeling (21 CFR 601.14) in Structured Product Labeling (SPL) format via the FDA automated drug registration and listing system, (eLIST) as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the Package Insert submitted on June 6, 2023. Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As* at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

All final labeling should be submitted as Product Correspondence to this BLA, STN BL 125591/0 at the time of use and include implementation information on Form FDA 356h.

ADVERTISING AND PROMOTIONAL LABELING

You may submit two draft copies of the proposed introductory advertising and promotional labeling with Form FDA 2253 to the Advertising and Promotional Labeling Branch at the following address:

Food and Drug Administration
Center for Biologics Evaluation and Research
Document Control Center
10903 New Hampshire Ave.
WO71–G112
Silver Spring, MD 20993-0002

You must submit copies of your final advertising and promotional labeling at the time of initial dissemination or publication, accompanied by Form FDA 2253 (21 CFR 601.12(f)(4)).

All promotional claims must be consistent with and not contrary to approved labeling. You should not make a comparative promotional claim or claim of superiority over other products unless you have substantial evidence or substantial clinical experience to support such claims (21 CFR 202.1(e)(6)).

PEDIATRIC REQUIREMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We note that you have fulfilled the pediatric study requirement for ages 0 to 17 years for this application.

We will include information contained in the above-referenced supplement in your BLA file.

Sincerely,

Celia Witten, PhD, MD
Acting Director
Division of Clinical Evaluation Hematology
Office of Clinical Evaluation
Office of Therapeutic Products
Center for Biologics Evaluation and Research